-
1
-
-
84855717861
-
Epidemiology of respiratory syncytial virus infection in preterm infants
-
Resch B, Kurath S, Manzoni P. Epidemiology of respiratory syncytial virus infection in preterm infants. Open Microbiol J. 2011;5:135-143.
-
(2011)
Open Microbiol J
, vol.5
, pp. 135-143
-
-
Resch, B.1
Kurath, S.2
Manzoni, P.3
-
2
-
-
84960077836
-
Lower respiratory tract infection caused by respiratory syncytial virus: Current management and new therapeutics
-
Respiratory Syncytial Virus Network (ReSViNET)
-
Mazur NI, Martinón-Torres F, Baraldi E, et al; Respiratory Syncytial Virus Network (ReSViNET). Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir Med. 2015;3:888-900.
-
(2015)
Lancet Respir Med
, vol.3
, pp. 888-900
-
-
Mazur, N.I.1
Martinón-Torres, F.2
Baraldi, E.3
-
3
-
-
84905228480
-
Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection
-
Committee on infectious diseases and bronchiolitis guidelines committee
-
Committee on infectious diseases and bronchiolitis guidelines committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:e620-638.
-
(2014)
Pediatrics
, vol.134
, pp. e620-e638
-
-
-
4
-
-
84925234244
-
Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants
-
Baraldi E, Lanari M, Manzoni P, et al. Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants. Ital J Pediatr. 2014;40:65.
-
(2014)
Ital J Pediatr
, vol.40
, pp. 65
-
-
Baraldi, E.1
Lanari, M.2
Manzoni, P.3
-
5
-
-
84930751431
-
Update of recommendations on the use of palivizumab as prophylaxis in RSV infections
-
Comité de Estándares de la SENeo
-
FiguerasAloy J, CarbonellEstrany X; Comité de Estándares de la SENeo. Update of recommendations on the use of palivizumab as prophylaxis in RSV infections. AnPediatr (Barc). 2015;82:199.e1-2.
-
(2015)
AnPediatr (Barc)
, vol.82
, pp. 199e1-199e2
-
-
FiguerasAloy, J.1
CarbonellEstrany, X.2
-
6
-
-
84941628695
-
Preventing hospitalizations for respiratory syncytial virus infection
-
Canadian Paediatric Society, Infectious Diseases and Immunization Committee
-
Robinson JL, Le Saux N; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Preventing hospitalizations for respiratory syncytial virus infection. Paediatr Child Health. 2015;20:321-333.
-
(2015)
Paediatr Child Health
, vol.20
, pp. 321-333
-
-
Robinson, J.L.1
Le Saux, N.2
-
7
-
-
84861470949
-
High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: A dilemma of specific prevention
-
Manzoni P, Paes B, Resch B, et al. High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention. Early Hum Dev. 2012;88(suppl 2):S34-S41.
-
(2012)
Early Hum Dev
, vol.88
, pp. S34-S41
-
-
Manzoni, P.1
Paes, B.2
Resch, B.3
-
8
-
-
84860306234
-
Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations
-
Paes B, Mitchell I, Li A, et al. Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. Eur J Pediatr. 2012;171:833-841.
-
(2012)
Eur J Pediatr
, vol.171
, pp. 833-841
-
-
Paes, B.1
Mitchell, I.2
Li, A.3
-
9
-
-
79960650624
-
CARESS: The Canadian registry of palivizumab
-
CARESS investigators
-
Mitchell I, Paes BA, Li A, et al; CARESS investigators. CARESS: the Canadian registry of palivizumab. Pediatr Infect Dis J. 2011;30:651-655.
-
(2011)
Pediatr Infect Dis J
, vol.30
, pp. 651-655
-
-
Mitchell, I.1
Paes, B.A.2
Li, A.3
-
10
-
-
84952870921
-
Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
-
Italian Society of Neonatology
-
Bollani L, Baraldi E, Chirico G, et al; Italian Society of Neonatology. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). Ital J Pediatr. 2015;41:97.
-
(2015)
Ital J Pediatr
, vol.41
, pp. 97
-
-
Bollani, L.1
Baraldi, E.2
Chirico, G.3
-
11
-
-
84887436227
-
-
Public Health England. Accessed January 31, 2016
-
Public Health England. Immunisation against infectious diseases. 2015. Available from: https://www.gov.uk/government/publications/respiratorysyncytial-virus-the-green-book-chapter-27a. Accessed January 31, 2016.
-
(2015)
Immunisation Against Infectious Diseases
-
-
-
12
-
-
84941963037
-
Serious adverse events in the canadian registry of children receiving palivizumab (caress) for respiratory syncytial virus prevention
-
CARESS investigators
-
Chen JJ, Chan P, Paes B, et al; CARESS investigators. Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for respiratory syncytial virus prevention. PLoS One. 2015;10:e0134711.
-
(2015)
PLoS One
, vol.10
, pp. e0134711
-
-
Chen, J.J.1
Chan, P.2
Paes, B.3
-
13
-
-
0034619028
-
Adverse drug reactions: Definitions, diagnosis, and management
-
Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255-1259.
-
(2000)
Lancet
, vol.356
, pp. 1255-1259
-
-
Edwards, I.R.1
Aronson, J.K.2
-
14
-
-
33745553210
-
Summary proceedings from the bronchopulmonary dysplasia group
-
Walsh MC, Szefler S, Davis J, et al. Summary proceedings from the bronchopulmonary dysplasia group. Pediatrics. 2006;117: S52-S56.
-
(2006)
Pediatrics
, vol.117
, pp. S52-S56
-
-
Walsh, M.C.1
Szefler, S.2
Davis, J.3
-
15
-
-
79960243558
-
A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease
-
Motavizumab Cardiac Study Group
-
Feltes TF, Sondheimer HM, Tulloh RM, et al; Motavizumab Cardiac Study Group. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res. 2011;70:186-191.
-
(2011)
Pediatr Res
, vol.70
, pp. 186-191
-
-
Feltes, T.F.1
Sondheimer, H.M.2
Tulloh, R.M.3
-
16
-
-
84901841907
-
Respiratory syncytial virus prophylaxis in Down syndrome: A prospective cohort study
-
CARESS investigators
-
Yi H, Lanctôt KL, Bont L, et al; CARESS investigators. Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study. Pediatrics. 2014;133:1031-1037.
-
(2014)
Pediatrics
, vol.133
, pp. 1031-1037
-
-
Yi, H.1
Lanctôt, K.L.2
Bont, L.3
-
17
-
-
84865430737
-
Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children
-
Robbie GJ, Zhao L, Mondick J, et al. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother. 2012;56:4927-4936.
-
(2012)
Antimicrob Agents Chemother
, vol.56
, pp. 4927-4936
-
-
Robbie, G.J.1
Zhao, L.2
Mondick, J.3
-
18
-
-
84887990669
-
Three monthly doses of palivizumab are not adequate for 5-month protection: A population pharmacokinetic analysis
-
La Via WV, Notario GF, Yu XQ, et al. Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis. Pulm Pharmacol Ther. 2013;26:666-671.
-
(2013)
Pulm Pharmacol Ther
, vol.26
, pp. 666-671
-
-
La Via, W.V.1
Notario, G.F.2
Yu, X.Q.3
-
19
-
-
16644372782
-
Palivizumab use in very premature infants in the neonatal intensive care unit
-
Wu SY, Bonaparte J, Pyati S. Palivizumab use in very premature infants in the neonatal intensive care unit. Pediatrics. 2004;114:e554-e556.
-
(2004)
Pediatrics
, vol.114
, pp. e554-e556
-
-
Wu, S.Y.1
Bonaparte, J.2
Pyati, S.3
-
20
-
-
0031729747
-
Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV
-
American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn
-
American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics. 1998;102:1211-1216.
-
(1998)
Pediatrics
, vol.102
, pp. 1211-1216
-
-
-
21
-
-
0031683919
-
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
-
The IMpact-RSV Study Group
-
The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531-537.
-
(1998)
Pediatrics
, vol.102
, pp. 531-537
-
-
-
22
-
-
84861466431
-
What is BPD in 2012 and what will BPD become?
-
Jobe AH. What is BPD in 2012 and what will BPD become? Early Hum Dev. 2012;88 Suppl 2:S27-S28.
-
(2012)
Early Hum Dev
, vol.88
, pp. S27-S28
-
-
Jobe, A.H.1
-
23
-
-
25144507172
-
Optimal timing and dosing intervals of palivizumab in premature neonates: Still some work to do
-
Manzoni P, Sala U, Gomirato G, et al. Optimal timing and dosing intervals of palivizumab in premature neonates: still some work to do. Pediatrics. 2005;115:1439-1440.
-
(2005)
Pediatrics
, vol.115
, pp. 1439-1440
-
-
Manzoni, P.1
Sala, U.2
Gomirato, G.3
-
24
-
-
0038350757
-
Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: Results from the Palivizumab Outcomes Registry
-
Palivizumab Outcomes Registry Study Group
-
Parnes C, Guillermin J, Habersang R, et al; Palivizumab Outcomes Registry Study Group. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry. Pediatr Pulmonol. 2003;35:484-489.
-
(2003)
Pediatr Pulmonol
, vol.35
, pp. 484-489
-
-
Parnes, C.1
Guillermin, J.2
Habersang, R.3
-
25
-
-
47149094332
-
Prevention of hospitalization due to respiratory syncytial virus: Results from the Palivizumab Outcomes Registry
-
Palivizumab Outcomes Registry Group
-
Frogel M, Nerwen C, Cohen A, et al; Palivizumab Outcomes Registry Group. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol. 2008;28:511-517.
-
(2008)
J Perinatol
, vol.28
, pp. 511-517
-
-
Frogel, M.1
Nerwen, C.2
Cohen, A.3
-
26
-
-
85006594230
-
-
Child Health British Columbia Committee
-
Child Health British Columbia Committee. BC guidelines for RSV infection immunoprophylaxis. Available from: http://www.neonatalcann.ca/Infant%20Eligibility/British%20Columbia/BC%20RSV%20Program%20 Manual%202014-2015.pdf.
-
BC Guidelines for RSV Infection Immunoprophylaxis
-
-
-
27
-
-
71949099031
-
Policy statements-modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections
-
American Academy of Pediatrics. Committee on Infectious Disease
-
American Academy of Pediatrics. Committee on Infectious Disease. Policy statements-modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124:1694-16701.
-
(2009)
Pediatrics
, vol.124
, pp. 1694-16701
-
-
-
28
-
-
84898427609
-
Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus
-
Makari D, Checchia PA, Devincenzo J. Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus. Hum Vaccin Immunother. 2014;10:607-614.
-
(2014)
Hum Vaccin Immunother
, vol.10
, pp. 607-614
-
-
Makari, D.1
Checchia, P.A.2
Devincenzo, J.3
-
29
-
-
84880152109
-
Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries
-
Paes B, Mitchell I, Li A, et al. Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries. Clin Dev Immunol. 2013;2013:917068.
-
(2013)
Clin Dev Immunol
, vol.2013
, pp. 917068
-
-
Paes, B.1
Mitchell, I.2
Li, A.3
|